Single-nucleotide-resolution genomic maps of -methylguanine from the glioblastoma drug temozolomide

Jasmina Büchel,Cécile Mingard,Vakil Takhaveev,Patricia B. Reinert,Giulia Keller,Tom Kloter,Sabrina M. Huber,Maureen McKeague,Shana J. Sturla
DOI: https://doi.org/10.1101/2023.12.12.571283
2024-01-22
Abstract:Temozolomide kills cancer cells by forming -methylguanine ( -MeG), which leads to apoptosis due to mismatch-repair overload. However, -MeG repair by -methylguanine-DNA methyltransferase (MGMT) contributes to drug resistance. Characterizing genomic profiles of -MeG could elucidate how -MeG accumulation is influenced by repair, but there are no methods to map genomic locations of -MeG. Here, we developed an immunoprecipitation- and polymerase-stalling-based method, termed -MeG-seq, to locate -MeG across the whole genome at single-nucleotide resolution. We analyzed -MeG formation and repair with regards to sequence contexts and functional genomic regions in glioblastoma-derived cell lines and evaluated the impact of MGMT. -MeG signatures were highly similar to mutational signatures from patients previously treated with temozolomide. Furthermore, MGMT did not preferentially repair -MeG with respect to sequence context, chromatin state or gene expression level, however, may protect oncogenes from mutations. Finally, we found an MGMT-independent strand bias in -MeG accumulation in highly expressed genes, suggesting an additional transcription-associated contribution to its repair. These data provide high resolution insight on how -MeG formation and repair is impacted by genome structure and regulation. Further, -MeG-seq is expected to enable future studies of DNA modification signatures as diagnostic markers for addressing drug resistance and preventing secondary cancers.
Cancer Biology
What problem does this paper attempt to address?